Alirocumab and Evolocumab are:: (A) NPGL1 inhibitors, (B) Microsomal transport protein inhibitors, (C) PCSK - 9 inhibitors, (D) Lipoprotein lipase inhibitors
Answer is C. PCSK - 9 expressed over many tissues which inhibits metabolism of LDL - receptors. Drugs like Alirocumab & Evolocumab inhibit PCSK - 9 and increased LDL - receptor turnover. Thus they decrease the levels of LDL.